S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Is New IPO Instacart Already Hitting Speed Bumps?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Is New IPO Instacart Already Hitting Speed Bumps?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Is New IPO Instacart Already Hitting Speed Bumps?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Is New IPO Instacart Already Hitting Speed Bumps?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NASDAQ:INFI

Infinity Pharmaceuticals (INFI) Stock Forecast, Price & News

$0.02
0.00 (0.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
$0.02
$0.03
50-Day Range
$0.02
$0.22
52-Week Range
$0.02
$1.30
Volume
613,225 shs
Average Volume
2.83 million shs
Market Capitalization
$1.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50

Infinity Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
7,042.9% Upside
$1.50 Price Target
Short Interest
Healthy
2.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Infinity Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$28,714 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars


INFI stock logo

About Infinity Pharmaceuticals (NASDAQ:INFI) Stock

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

INFI Price History

INFI Stock News Headlines

This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Experts: NVIDIA Now "Too Big to Succeed"
Several of the market’s top analysts are sounding the alarm that NVIDIA’s share price may have reached its breaking point.
Infinity Shareholder Notice
Infinity Shareholder Action Reminder
See More Headlines
Receive INFI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INFI Company Calendar

Last Earnings
8/10/2023
Today
9/22/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INFI
CUSIP
45665G30
Employees
30
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$1.50
High Stock Price Forecast
$1.50
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+7,042.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-44,370,000.00
Net Margins
-1,593.93%
Pretax Margin
-1,593.93%

Debt

Sales & Book Value

Annual Sales
$2.57 million
Book Value
($0.21) per share

Miscellaneous

Free Float
81,857,000
Market Cap
$1.91 million
Optionable
Optionable
Beta
1.38

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Ms. Adelene Q. Perkins (Age 63)
    Chairman & CEO
    Comp: $701.51k
  • Dr. Robert Ilaria Jr. (Age 62)
    M.D., Chief Medical Officer
    Comp: $653.8k
  • Dr. Lawrence E. Bloch J.D. (Age 57)
    M.D., Treasurer
    Comp: $513.61k
  • Ms. Melissa Hackel
    VP of Fin.
  • Dr. Stephane Peluso Ph.D. (Age 52)
    Chief Scientific Officer
  • Mr. Seth A. Tasker J.D. (Age 44)
    Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec.













INFI Stock - Frequently Asked Questions

Should I buy or sell Infinity Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INFI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INFI, but not buy additional shares or sell existing shares.
View INFI analyst ratings
or view top-rated stocks.

What is Infinity Pharmaceuticals' stock price forecast for 2023?

2 analysts have issued 1-year price targets for Infinity Pharmaceuticals' stock. Their INFI share price forecasts range from $1.50 to $1.50. On average, they anticipate the company's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 7,042.9% from the stock's current price.
View analysts price targets for INFI
or view top-rated stocks among Wall Street analysts.

How have INFI shares performed in 2023?

Infinity Pharmaceuticals' stock was trading at $0.5550 at the beginning of the year. Since then, INFI stock has decreased by 96.2% and is now trading at $0.0210.
View the best growth stocks for 2023 here
.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,210,000 shares, an increase of 12.2% from the August 15th total of 1,970,000 shares. Based on an average trading volume of 3,370,000 shares, the days-to-cover ratio is currently 0.7 days.
View Infinity Pharmaceuticals' Short Interest
.

When is Infinity Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our INFI earnings forecast
.

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) announced its quarterly earnings data on Thursday, August, 10th. The biotechnology company reported ($0.11) EPS for the quarter. The biotechnology company earned $0.58 million during the quarter.

What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO?

10 employees have rated Infinity Pharmaceuticals Chief Executive Officer Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among the company's employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

Who are Infinity Pharmaceuticals' major shareholders?

Infinity Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Carlson Capital L P (1.45%), Renaissance Technologies LLC (0.40%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Adelene Q Perkins and Bvf Partners L P/Il.
View institutional ownership trends
.

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $0.02.

How much money does Infinity Pharmaceuticals make?

Infinity Pharmaceuticals (NASDAQ:INFI) has a market capitalization of $1.91 million and generates $2.57 million in revenue each year. The biotechnology company earns $-44,370,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The official website for the company is www.infi.com. The biotechnology company can be reached via phone at (617) 453-1000, via email at irpr_info@infi.com, or via fax at 617-453-1001.

This page (NASDAQ:INFI) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -